ETFIS Series Trust I (PFFR) NPORT-P Virtus LifeSci Biotech Clinical Trials ETF (Jul 2024 report)

Schedule of Investments - Virtus LifeSci Biotech Clinical Trials ETF

July 31, 2024 (unaudited)

Security Description	Shares		Value
COMMON STOCKS - 98.1%
Health Care - 98.1%
4D Molecular Therapeutics, Inc.*		3,709	$	65,761
89bio, Inc.*		9,744		89,255
AbCellera Biologics, Inc. (Canada)*		27,185		88,623
ACELYRIN, Inc.*(1)		20,763		124,578
Aerovate Therapeutics, Inc.*		3,683		6,703
Agenus, Inc.*(1)		5,658		34,174
Akero Therapeutics, Inc.*		3,677		98,286
Alector, Inc.*		18,362		110,172
Allogene Therapeutics, Inc.*		35,640		104,782
ALX Oncology Holdings, Inc.*		10,726		51,485
AnaptysBio, Inc.*		3,733		130,058
Annexon, Inc.*		15,063		96,554
Apogee Therapeutics, Inc.*		2,099		102,221
Applied Therapeutics, Inc.*		17,210		102,227
Arbutus Biopharma Corp.*		28,647		107,999
Arcellx, Inc.*		1,623		100,318
Arcturus Therapeutics Holdings, Inc.*		2,865		67,213
Arcus Biosciences, Inc.*(1)		5,325		87,383
Arcutis Biotherapeutics, Inc.*		9,692		97,598
Arrowhead Pharmaceuticals, Inc.*		3,416		97,561
Arvinas, Inc.*		3,423		94,167
Autolus Therapeutics PLC (United Kingdom)*(2)		19,984		93,725
Avidity Biosciences, Inc.*		2,265		103,239
Beam Therapeutics, Inc.*(1)		3,587		113,493
Belite Bio, Inc.*(1)(2)		1,807		89,447
Bicycle Therapeutics PLC (United Kingdom)*(2)		3,725		90,555
Biohaven Ltd.*		2,710		106,584
Cabaletta Bio, Inc.*		7,207		51,170
Cargo Therapeutics, Inc.*		5,269		89,731
Cassava Sciences, Inc.*(1)		4,551		101,123
Celcuity, Inc.*		5,901		108,165
Celldex Therapeutics, Inc.*		2,485		94,703
Centessa Pharmaceuticals PLC*(1)(2)		9,116		95,991
CG oncology, Inc.*		2,601		86,743
Cogent Biosciences, Inc.*		10,081		95,064
Compass Pathways PLC (United Kingdom)*(2)		13,044		99,526
Crinetics Pharmaceuticals, Inc.*		1,931		102,575
Cullinan Therapeutics, Inc.*		4,153		80,361
CureVac NV (Germany)*(1)		22,631		85,319
Cytokinetics, Inc.*		1,717		101,320
Denali Therapeutics, Inc.*		4,092		99,722
Dianthus Therapeutics, Inc.*		3,358		100,001
Disc Medicine, Inc.*		2,312		99,786
Dyne Therapeutics, Inc.*		2,687		115,299
Edgewise Therapeutics, Inc.*		5,054		86,070
Editas Medicine, Inc.*		16,489		89,205
Enliven Therapeutics, Inc.*		4,111		108,448
Erasca, Inc.*		41,526		130,807
Exscientia PLC (United Kingdom)*(1)(2)		19,018		100,605
Fulcrum Therapeutics, Inc.*		11,606		107,704
HilleVax, Inc.*		6,117		11,194
Ideaya Biosciences, Inc.*		2,325		100,091
IGM Biosciences, Inc.*(1)		11,401		127,235
Immatics NV (Germany)*		6,990		84,020
Immunome, Inc.*(1)		5,644		86,974
Immunovant, Inc.*(1)		3,403		98,925
Intellia Therapeutics, Inc.*(1)		3,487		91,394
iTeos Therapeutics, Inc.*		5,554		97,695

Security Description	Shares		Value
COMMON STOCKS (continued)
Health Care (continued)
Janux Therapeutics, Inc.*		2,137	$	86,762
Keros Therapeutics, Inc.*		1,829		91,743
Kura Oncology, Inc.*		4,197		87,340
Kymera Therapeutics, Inc.*(1)		2,596		119,935
Kyverna Therapeutics, Inc.*(1)		6,269		54,290
Larimar Therapeutics, Inc.*		9,342		78,379
Liquidia Corp.*		6,741		80,420
Longboard Pharmaceuticals, Inc.*		4,538		150,843
Lyell Immunopharma, Inc.*		34,952		56,273
MacroGenics, Inc.*		19,343		72,730
Merus NV (Netherlands)*		1,570		83,273
Mineralys Therapeutics, Inc.*		7,134		88,390
MoonLake Immunotherapeutics*		2,120		88,298
Morphic Holding, Inc.*		3,262		184,825
Neumora Therapeutics, Inc.*(1)		9,098		117,000
Neurogene, Inc.*(1)		2,156		88,698
Newamsterdam Pharma Co. NV (Netherlands)*		4,657		79,728
Nurix Therapeutics, Inc.*		5,411		118,393
Nuvalent, Inc. Class A*(1)		1,146		91,611
Nuvation Bio, Inc.*		30,276		115,957
Olema Pharmaceuticals, Inc.*		7,265		117,402
ORIC Pharmaceuticals, Inc.*(1)		11,787		132,014
Perspective Therapeutics, Inc.*		7,803		106,121
Pharvaris NV (Netherlands)*		5,001		85,717
Pliant Therapeutics, Inc.*		7,563		108,227
Praxis Precision Medicines, Inc.*		2,260		130,425
Precigen, Inc.*		53,250		80,940
Prime Medicine, Inc.*		11,459		64,285
Protagonist Therapeutics, Inc.*		2,635		98,654
Prothena Corp. PLC (Ireland)*		4,236		98,614
Recursion Pharmaceuticals, Inc. Class A*(1)		9,590		78,638
REGENXBIO, Inc.*		6,921		98,624
Relay Therapeutics, Inc.*		11,569		95,097
Replimune Group, Inc.*		9,569		95,690
REVOLUTION Medicines, Inc.*		2,278		103,968
Rocket Pharmaceuticals, Inc.*(1)		3,960		95,832
Sana Biotechnology, Inc.*		12,661		77,105
Savara, Inc.*		22,297		102,566
Scholar Rock Holding Corp.*		9,600		87,168
Scilex Holding Co. (Singapore)*(3)(4)		17,635		25,236
Silence Therapeutics PLC (United Kingdom)*(2)		4,591		94,116
Soleno Therapeutics, Inc.*		2,011		96,991
Spyre Therapeutics, Inc.*		2,797		76,917
Stoke Therapeutics, Inc.*		5,167		77,350
Structure Therapeutics, Inc.*(1)(2)		1,753		65,545
Summit Therapeutics, Inc.*(1)		11,190		120,852
Syndax Pharmaceuticals, Inc.*		4,373		99,267
Tango Therapeutics, Inc.*		10,790		106,282
Taysha Gene Therapies, Inc.*		21,709		47,977
Terns Pharmaceuticals, Inc.*		11,344		87,916
Tyra Biosciences, Inc.*		4,560		101,050
uniQure NV (Netherlands)*		17,243		132,081
Vaxcyte, Inc.*		1,223		96,482
Vera Therapeutics, Inc.*		2,420		88,548
Verve Therapeutics, Inc.*(1)		16,165		113,155
Viking Therapeutics, Inc.*		1,738		99,066
Vir Biotechnology, Inc.*		8,738		88,778
Viridian Therapeutics, Inc.*		6,884		115,995
WaVe Life Sciences Ltd.*		13,970		92,342
Xencor, Inc.*		4,248		86,744

Schedule of Investments - Virtus LifeSci Biotech Clinical Trials ETF (continued)

July 31, 2024 (unaudited)

Security Description	Shares		Value
COMMON STOCKS (continued)
Health Care (continued)
Xenon Pharmaceuticals, Inc. (Canada)*		2,380	$	102,649
Zentalis Pharmaceuticals, Inc.*		9,509		36,990
Zymeworks, Inc.*		9,937		103,941
Total Health Care				11,329,372
Total Common Stocks
(Cost $12,467,161)				11,329,372
SECURITIES LENDING COLLATERAL - 7.6%
Money Market Fund - 7.6%
Dreyfus Government Cash Management Fund, Institutional Shares, 5.21%(5)(6)
(Cost $875,541)		875,541		875,541
TOTAL INVESTMENTS - 105.7%
(Cost $13,342,702)				12,204,913
Liabilities in Excess of Other Assets - (5.7)%				(661,172	)
Net Assets - 100.0%			$	11,543,741

*	Non-income producing security.
(1)	All or a portion of the security was on loan. The aggregate market value of securities on loan was $1,723,609; total market value of collateral held by the Fund was $1,727,739. Market value of the collateral held includes non-cash U.S. Treasury securities having a value of $852,198.
(2)	American Depositary Receipts.
(3)	Security valued at fair value as determined in good faith by or under the direction of the Trustees. This security is disclosed as a Level 3 security in the Fair Value Hierarchy table located after the Schedule of Investments.
(4)	Restricted security.
(5)	Represents securities purchased with cash collateral received for securities on loan.
(6)	The rate shown reflects the seven-day yield as of July 31, 2024.

Schedule of Investments - Virtus LifeSci Biotech Clinical Trials ETF (continued)

July 31, 2024 (unaudited)

Fair Value Measurements

The Fund utilizes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access. Level 2 includes observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data. Level 3 includes unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following table summarizes valuation of the Fund’s investments under the fair value hierarchy levels as of July 31, 2024.

	Level 1		Level 2		Level 3		Total
Asset Valuation Inputs
Common Stocks	$	11,304,136	$	—	$	25,236	$	11,329,372
Money Market Fund		—		—		—		875,541
Total	$	11,304,136	$	—	$	25,236	$	12,204,913

Management has determined that the amount of Level 3 securities compared to total net assets is not material; therefore, the rollforward of Level 3 securities and assumptions are not shown for the period ended July 31, 2024.